Aspirin reduces the risk of type 2 diabetes associated with COVID-19.

Trimarco, Valentina, Raffaele Izzo, Daniela Pacella, Maria Virginia Manzi, Stanislovas S Jankauskas, Paola Gallo, Francesco Rozza, et al. “Aspirin Reduces the Risk of Type 2 Diabetes Associated With COVID-19.”. Npj Metabolic Health and Disease. 3, no. 1 (2025): 27.

Abstract

This study aimed to determine whether daily low-dose aspirin reduces the risk of type 2 diabetes (T2D) associated with COVID-19. A longitudinal cohort of 200,000 adults followed from 2018 to 2022 was analyzed, comparing T2D incidence between aspirin users and non-users. Propensity score matching was used to balance the groups. The incidence of T2D was substantially lower in the aspirin group, with Cox regression showing a 52% risk reduction. Kaplan-Meier analysis confirmed a significant divergence in cumulative T2D risk after two years. This protective effect was observed both before and during the COVID-19 pandemic, with a stronger association during the pandemic period. These findings indicate that daily low-dose aspirin significantly reduces the risk of COVID-19-associated new-onset T2D, highlighting the role of inflammation in the pathogenesis of T2D triggered or unmasked by COVID-19.

Last updated on 07/03/2025
PubMed